United States - English - NLM (National Library of Medicine)

sun pharmaceuticals industries, inc. - dexmedetomidine hydrochloride (unii: 1018wh7f9i) (dexmedetomidine - unii:67vb76hono) - dexmedetomidine 100 ug in 1 ml - dexmedetomidine hydrochloride injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures. none pregnancy category c: there are no adequate and well-controlled studies of dexmedetomidine hydrochloride use in pregnant women.  in an in vitro human placenta study, placental transfer of dexmedetomidine occurred. in a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.  thus, fetal exposure should be expected in humans, and dexmedetomidine hydrochloride should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. teratogenic effects were not observed in rats following subcutaneous administration of dexmedetomidine during the period of fetal organogenesis (from gestation day 5 to 16) with doses up to 200 mcg/kg (representing a dose approximately equal to the maximum recommended human intravenous dose based on body surface

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ondansetron hydrochloride dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ondansetron hydrochloride dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.986 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; lactose; titanium dioxide; hypromellose; microcrystalline cellulose; triacetin - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.972 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; lactose; titanium dioxide; hypromellose; triacetin; iron oxide yellow - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - alfentanil hydrochloride - solution for injection - 500microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - alfentanil hydrochloride - solution for injection - 500microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - alfentanil hydrochloride - solution for injection - 500microgram/1ml